Efficacy and Safety of mitapivat in a subset of hereditary hemolytic anemias: a systematic review, meta-analysis, and GRADE assessment of randomized controlled trials

Hereditary hemolytic anemias (HHAs) comprise biologically distinct disorders with limited disease-modifying treatment options. Mitapivat, an oral pyruvate kinase activator, has emerged as a promising metabolic therapy, but its overall efficacy and safety across HHAs remain incompletely defined. We synthesized randomized evidence comparing mitapivat with placebo across subset of HHA. A systematic review and meta-analysis of RCTs was conducted according to PRISMA guidelines (PROSPERO: CRD420261469200). The databases PubMed, Embase, Scopus, Cochrane Library, Google Scholar and ClinicalTrials.gov were searched up to May 2026. Placebo-controlled trials evaluating mitapivat in patients with hereditary hemolytic anemias were included. Random-effects meta-analyses were performed using RevMan 5.4. Risk of bias was assessed using the Cochrane Risk of Bias 2.0 tool, and evidence certainty was evaluated using GRADE. Four double-blind randomized controlled trials involving 585 participants with pyruvate kinase deficiency, sickle cell disease, and thalassemia were included. Mitapivat demonstrated a striking improvement in hemoglobin response, with patients more than 20 times as likely to achieve a response compared with placebo (RR, 21.33; 95% CI, 6.18–73.66; I²=0%). Hemoglobin concentration also improved significantly (SMD, 1.28; 95% CI, 1.04–1.53; I²=0%). These hematologic benefits were accompanied by significant reductions in indirect bilirubin (SMD, − 0.92; 95% CI, − 1.18 to − 0.66; I²=0%) and lactate dehydrogenase (SMD, − 0.45; 95% CI, − 0.80 to − 0.09; I²=44%). Overall adverse events were comparable between groups (RR, 1.05; 95% CI, 0.98–1.13), although grade ≥ 3 and treatment-related adverse events occurred more frequently with mitapivat. Mitapivat produced consistent and clinically meaningful improvements in hematologic and biochemical markers of hemolysis across subset of HHAs. However, the increased frequency of severe and treatment-related adverse events highlights the need for careful monitoring. Further disease-specific studies with longer follow-up are warranted to establish its long-term clinical benefits and safety.

Authors

Institutions

Publication Details

Journal
Annals of Hematology
Published
2026-11-20
DOI
https://doi.org/10.1007/s00277-026-07364-8
Primary Topic
Hemoglobinopathies and Related Disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Efficacy and Safety of mitapivat in a subset of hereditary hemolytic anemias: a systematic review, meta-analysis, and GRADE assessment of randomized controlled trials

M. MUZAFFAR KHAN, Maryam Abbasi, Kainat Mehmood, Manal Jamal Al-Dhaheri et al.
2 links
Annals of Hematology
Hemoglobinopathies and Related Disorders
article

Efficacy and Safety of mitapivat in a subset of hereditary hemolytic anemias: a systematic review, meta-analysis, and GRADE assessment of randomized controlled trials

M. MUZAFFAR KHAN, Maryam Abbasi, Kainat Mehmood, Manal Jamal Al-Dhaheri, Hafsa Ahsun, Zain Shahzad, Humayou Ahmed, Mohammad Hassan, Maheen Hamid, Sameen Fida, Daniyal Zulfiqar, Muhammad Rayyan Humayun
article en

Abstract

Hereditary hemolytic anemias (HHAs) comprise biologically distinct disorders with limited disease-modifying treatment options. Mitapivat, an oral pyruvate kinase activator, has emerged as a promising metabolic therapy, but its overall efficacy and safety across HHAs remain incompletely defined. We synthesized randomized evidence comparing mitapivat with placebo across subset of HHA. A systematic review and meta-analysis of RCTs was conducted according to PRISMA guidelines (PROSPERO: CRD420261469200). The databases PubMed, Embase, Scopus, Cochrane Library, Google Scholar and ClinicalTrials.gov were searched up to May 2026. Placebo-controlled trials evaluating mitapivat in patients with hereditary hemolytic anemias were included. Random-effects meta-analyses were performed using RevMan 5.4. Risk of bias was assessed using the Cochrane Risk of Bias 2.0 tool, and evidence certainty was evaluated using GRADE. Four double-blind randomized controlled trials involving 585 participants with pyruvate kinase deficiency, sickle cell disease, and thalassemia were included. Mitapivat demonstrated a striking improvement in hemoglobin response, with patients more than 20 times as likely to achieve a response compared with placebo (RR, 21.33; 95% CI, 6.18–73.66; I²=0%). Hemoglobin concentration also improved significantly (SMD, 1.28; 95% CI, 1.04–1.53; I²=0%). These hematologic benefits were accompanied by significant reductions in indirect bilirubin (SMD, − 0.92; 95% CI, − 1.18 to − 0.66; I²=0%) and lactate dehydrogenase (SMD, − 0.45; 95% CI, − 0.80 to − 0.09; I²=44%). Overall adverse events were comparable between groups (RR, 1.05; 95% CI, 0.98–1.13), although grade ≥ 3 and treatment-related adverse events occurred more frequently with mitapivat. Mitapivat produced consistent and clinically meaningful improvements in hematologic and biochemical markers of hemolysis across subset of HHAs. However, the increased frequency of severe and treatment-related adverse events highlights the need for careful monitoring. Further disease-specific studies with longer follow-up are warranted to establish its long-term clinical benefits and safety.

Annals of Hematology
Services Institute of Medical Sciences (PK), Sana'a University (YE), Allama Iqbal Medical College (PK), Jinnah Sindh Medical University (PK), Dow University of Health Sciences (PK)
Good health and well-being
Hemoglobinopathies and Related Disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon